22287754
2012 Feb
Background:No reliable prognostic predictor is known for patients undergoing sorafenib treatment for advanced hepatocellular carcinoma (HCC).Patients and methods:In 81 patients receiving sorafenib treatment for advanced HCC, we evaluated the prognostic significance of an inflammation-based prognostic score, the Glasgow prognostic score [evidenced by an elevated C-reactive protein level (>1.0 mg/dl) and hypoalbuminemia (Results:Median overall survival after sorafenib administration was 11.3 months. On multivariate analysis, Glasgow prognostic score (0 vs. 1 and 2; pConclusion:The Glasgow prognostic score has significant prognostic value in patients undergoing sorafenib treatment for advanced HCC.

